Michael Decker

List of Publications by Year
in descending order

116 papers	3,223 citations	136950 32 h-index	182427 51 g-index
126 all docs	126 docs citations	126 times ranked	3581 citing authors

#	Article	IF	Citations
1	Photoswitchable Pseudoirreversible Butyrylcholinesterase Inhibitors Allow Optical Control of Inhibition in Vitro and Enable Restoration of Cognition in an Alzheimerâ€™s Disease Mouse Model upon Irradiation. Journal of the American Chemical Society, 2022, 144, 3279-3284.	13.7	22
2	Die Erhellung des â€œBewusstseinsmolekÃ¼lsâ€• Photomodulation des 5â€HT_{2A} Rezeptors durch ein lichtâ€steuerbares N,Nâ€Dimethyltryptaminâ€Derivat. Angewandte Chemie, 2022, 134, .	2.0	1
3	Enlightening the â€œSpirit Moleculeâ€• Photomodulation of the 5â€HT_{2A} Receptor by a Lightâ€Controllable N,Nâ€Dimethyltryptamine Derivative. Angewandte Chemie - International Edition, 2022, 61, .	13.8	10
4	Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype. ChemMedChem, 2022, 17, .	3.2	4
5	Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model. RSC Medicinal Chemistry, 2022, 13, 944-954.	3.9	2
6	Frontispiz: Die Erhellung des â€œBewusstseinsmolekÃ¼lsâ€• Photomodulation des 5â€HT_{2A} Rezeptors durch ein lichtâ€steuerbares N,Nâ€Dimethyltryptaminâ€Derivat. Angewandte Chemie, 2022, 134, .	2.0	0
7	Frontispiece: Enlightening the â€œSpirit Moleculeâ€• Photomodulation of the 5â€HT_{2A} Receptor by a Lightâ€Controllable N,Nâ€Dimethyltryptamine Derivative. Angewandte Chemie - International Edition, 2022, 61, .	13.8	0
8	Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase. Molecular Imaging and Biology, 2021, 23, 505-515.	2.6	4
9	Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimerâ€™s Disease Mouse Model. Journal of Medicinal Chemistry, 2021, 64, 3794-3812.	6.4	34
10	Azobioisosteres of Curcumin with Pronounced Activity against Amyloid Aggregation, Intracellular Oxidative Stress, and Neuroinflammation. Chemistry - A European Journal, 2021, 27, 6015-6027.	3.3	4
11	Synthesis and Initial Characterization of a Selective, Pseudoâ€irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer. ChemMedChem, 2021, 16, 1427-1437.	3.2	6
12	â€œPhoto-Rimonabantâ€• Synthesis and Biological Evaluation of Novel Photoswitchable Molecules Derived from Rimonabant Lead to a Highly Selective and Nanomolar â€œCis-Onâ€•CB₁R Antagonist. ACS Chemical Neuroscience, 2021, 12, 1632-1647.	3.5	17
13	Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimerâ€™s Disease Mouse Model. Journal of Medicinal Chemistry, 2021, 64, 9302-9320.	6.4	26
14	The Structure of Cyclodecatriene Collinolactone, its Biosynthesis, and Semisynthetic Analogues: Effects of Monoastral Phenotype and Protection from Intracellular Oxidative Stress. Angewandte Chemie - International Edition, 2021, 60, 23212-23216.	13.8	5
15	Die Struktur des Cyclodecatriens Collinolacton, seine Biosynthese und semisynthetische Derivate: monopolare Spindeln und Schutz vor intrazellulÃrem oxidativem Stress. Angewandte Chemie, 2021, 133, 23399.	2.0	0
16	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. European Journal of Medicinal Chemistry, 2021, 225, 113779.	5.5	7
17	Photopharmacology on Acetylcholinesterase: Novel Photoswitchable Inhibitors with Improved Pharmacological Profiles. ChemPhotoChem, 2021, 5, 149-159.	3.0	11
18	Initial Evaluation of AF78: a Rationally Designed Fluorine-18-Labelled PET Radiotracer Targeting Norepinephrine Transporter. Molecular Imaging and Biology, 2020, 22, 602-611.	2.6	11

#	Article	IF	Citations
19	Selective and Washâ€Resistant Fluorescent Dihydrocodeinone Derivatives Allow Singleâ€Molecule Imaging of Î¼â€Opioid Receptor Dimerization. Angewandte Chemie - International Edition, 2020, 59, 5958-5964.	13.8	23
20	Selective and Washâ€Resistant Fluorescent Dihydrocodeinone Derivatives Allow Singleâ€Molecule Imaging of Î¼â€Opioid Receptor Dimerization. Angewandte Chemie, 2020, 132, 6014-6020.	2.0	5
21	7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo. Redox Biology, 2020, 29, 101378.	9.0	49
22	Development and Application of a Chemical Probe Based on a Neuroprotective Flavonoid Hybrid for Target Identification Using Activity-Based Protein Profiling. ACS Chemical Neuroscience, 2020, 11, 3823-3837.	3.5	11
23	Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo. Chemistry - A European Journal, 2020, 26, 7299-7308.	3.3	23
24	Investigation of Inactive-State Îº Opioid Receptor Homodimerization via Single-Molecule Microscopy Using New Antagonistic Fluorescent Probes. Journal of Medicinal Chemistry, 2020, 63, 3596-3609.	6.4	12
25	N-1,2,3-triazole-isatin derivatives for cholinesterase and Î²-amyloid aggregation inhibition: A comprehensive bioassay study. Bioorganic Chemistry, 2020, 98, 103753.	4.1	32
26	InnenrÃ¼cktitelbild: Selective and Washâ€Resistant Fluorescent Dihydrocodeinone Derivatives Allow Singleâ€Molecule Imaging of Î¼â€Opioid Receptor Dimerization (Angew. Chem. 15/2020). Angewandte Chemie, 2020, 132, 6348-6348.	2.0	1
27	Development and Biological Applications of Fluorescent Opioid Ligands. ChemPlusChem, 2020, 85, 1354-1364.	2.8	13
28	Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes. ChemMedChem, 2020, 15, 1374-1389.	3.2	15
29	Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. European Journal of Medicinal Chemistry, 2019, 180, 690-706.	5.5	26
30	Dual-Acting Cholinesteraseâ€“Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. Journal of Medicinal Chemistry, 2019, 62, 9078-9102.	6.4	35
31	Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimerâ€™s Disease Mouse Model. Journal of Medicinal Chemistry, 2019, 62, 9116-9140.	6.4	59
32	(R)â€Tonkafuranone and related compounds: Improved synthesis, stereochemical purity in nature, and bioactivities of the pure enantiomers. Flavour and Fragrance Journal, 2019, 34, 329-338.	2.6	1
33	Novel BQCAâ€and TBPBâ€Derived M 1 Receptor Hybrid Ligands: Orthosteric Carbachol Differentially Regulates Partial Agonism. ChemMedChem, 2019, 14, 1349-1358.	3.2	6
34	Optical Control of Cardiac Function with a Photoswitchable Muscarinic Agonist. Journal of the American Chemical Society, 2019, 141, 7628-7636.	13.7	52
35	Fluorination of Photoswitchable Muscarinic Agonists Tunes Receptor Pharmacology and Photochromic Properties. Journal of Medicinal Chemistry, 2019, 62, 3009-3020.	6.4	31
36	Structureâ€“Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles. Journal of Medicinal Chemistry, 2018, 61, 1646-1663.	6.4	50

#	Article	IF	Citations
37	The First Photochromic Affinity Switch for the Human Cannabinoid Receptor 2. Advanced Therapeutics, 2018, 1, 1700032.	3.2	20
38	Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects. European Journal of Medicinal Chemistry, 2018, 146, 93-107.	5.5	19
39	¹⁸Fâ€Labeled Derivatives of Irbesartan for Angiotensinâ€...II Receptor PET Imaging. ChemMedChem, 2018, 13, 2546-2557.	3.2	9
40	Investigations into neuroprotectivity, stability, and water solubility of 7â€Oâ€cinnamoylsilibinin, its hemisuccinate and dehydro derivatives. Archiv Der Pharmazie, 2018, 351, e1800206.	4.1	8
41	Novel ¹⁸F-Labeled PET Imaging Agent FV45 Targeting the Reninâ€“Angiotensin System. ACS Omega, 2018, 3, 10460-10470.	3.5	11
42	Photopharmacology in Alzheimer's Disease. Advanced Therapeutics, 2018, 1, 1800037.	3.2	8
43	Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1. Expert Opinion on Therapeutic Patents, 2017, 27, 121-125.	5.0	0
44	A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy. Angewandte Chemie - International Edition, 2017, 56, 7282-7287.	13.8	61
45	Natural antioxidants in hybrids for the treatment of neurodegenerative diseases: a successful strategy?. Future Medicinal Chemistry, 2017, 9, 711-713.	2.3	9
46	Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M₁and M₂. MedChemComm, 2017, 8, 1346-1359.	3.4	10
47	Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance. Human Cell, 2017, 30, 267-278.	2.7	6
48	Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4937-4941.	2.2	17
49	Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors. , 2017, , 137-165.		6
50	Ein photoschaltbarer Ligand zur Regulierung der Rezeptoraktivierung. Angewandte Chemie, 2017, 129, 7388-7393.	2.0	14
51	Photoresponsive Hybrid Compounds. , 2017, , 279-315.		5
52	Experimental and theoretical investigations into the stability of cyclic aminals. Beilstein Journal of Organic Chemistry, 2016, 12, 2280-2292.	2.2	20
53	Unconventional application of the Mitsunobu reaction: Selective flavonolignan dehydration yielding hydnocarpins. Beilstein Journal of Organic Chemistry, 2016, 12, 662-669.	2.2	10
54	Aminobenzimidazoles and Structural Isomers as Templates for Dualâ€Acting Butyrylcholinesterase Inhibitors and hCB₂R Ligands To Combat Neurodegenerative Disorders. ChemMedChem, 2016, 11, 1270-1283.	3.2	28

#	Article	IF	Citations
55	Investigation into the stability and reactivity of the pentacyclic alkaloid dehydroevodiamine and the benz-analog thereof. Tetrahedron, 2016, 72, 2535-2543.	1.9	9
56	The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats. Physiology and Behavior, 2016, 165, 383-391.	2.1	33
57	Perception of the Relevance of Organic Chemistry in a German Pharmacy Studentsâ€™ Course. American Journal of Pharmaceutical Education, 2016, 80, 40.	2.1	11
58	A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety. ChemMedChem, 2016, 11, 1540-1550.	3.2	15
59	Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aî²_{1â"42} Aggregation Inhibitors for Alzheimer's Disease Therapy. ChemMedChem, 2016, 11, 1318-1327.	3.2	24
60	Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode. Journal of Medicinal Chemistry, 2016, 59, 2067-2082.	6.4	76
61	The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats. Behavioural Brain Research, 2016, 297, 155-164.	2.2	36
62	Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties. Archiv Der Pharmazie, 2015, 348, 531-540.	4.1	7
63	Radionuclide Imaging of Neurohormonal System of the Heart. Theranostics, 2015, 5, 545-558.	10.0	26
64	New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds. ChemMedChem, 2015, 10, 773-786.	3.2	26
65	Novel Tacrineâ€Grafted Ugi Adducts as Multipotent Antiâ€Alzheimer Drugs: A Synthetic Renewal in Tacrineâ€"Ferulic Acid Hybrids. ChemMedChem, 2015, 10, 523-539.	3.2	62
66	Rational Design of Partial Agonists for the Muscarinic M₁ Acetylcholine Receptor. Journal of Medicinal Chemistry, 2015, 58, 560-576.	6.4	35
67	Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4209-4214.	2.2	16
68	Investigation into selective debenzylation and ring cleavage of quinazoline based heterocycles. Tetrahedron Letters, 2014, 55, 2973-2976.	1.4	11
69	Synthesis, Biological Evaluation, and Computational Studies of Tri- and Tetracyclic Nitrogen-Bridgehead Compounds as Potent Dual-Acting AChE Inhibitors and hH₃ Receptor Antagonists. ACS Chemical Neuroscience, 2014, 5, 225-242.	3.5	67
70	A simple heterocyclic fusion reaction and its application for expeditious syntheses of rutaecarpine and its analogs. Tetrahedron Letters, 2014, 55, 3607-3609.	1.4	40
71	Flavonoids, Flavonoid Metabolites, and Phenolic Acids Inhibit Oxidative Stress in the Neuronal Cell Line HT-22 Monitored by ECIS and MTT Assay: A Comparative Study. Journal of Natural Products, 2014, 77, 446-454.	3.0	38
72	Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2014, 22, 5020-5034.	3.0	14

#	Article	IF	Citations
73	Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties. Bioorganic and Medicinal Chemistry, 2014, 22, 3938-3946.	3.0	19
74	Acetylcholinesterase Inhibitors with Photoswitchable Inhibition of Î²-Amyloid Aggregation. ACS Chemical Neuroscience, 2014, 5, 377-389.	3.5	96
75	Amine substitution of quinazolinones leads to selective nanomolar AChE inhibitors with â€˜invertedâ€™ binding mode. Bioorganic and Medicinal Chemistry, 2014, 22, 4867-4881.	3.0	48
76	Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. European Journal of Medicinal Chemistry, 2014, 81, 15-21.	5.5	63
77	In-vitro stability and metabolism of a tacrineâ€“silibinin codrug. Journal of Pharmacy and Pharmacology, 2013, 65, 1765-1772.	2.4	12
78	Alzheimer mit HybridmolekÃ¼len in die Zange nehmen. Nachrichten Aus Der Chemie, 2013, 61, 871-875.	0.0	0
79	Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer. ACS Medicinal Chemistry Letters, 2012, 3, 914-919.	2.8	79
80	M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease. MedChemComm, 2012, 3, 752.	3.4	22
81	Tacrine-Silibinin Codrug Shows Neuro- and Hepatoprotective Effects in Vitro and Pro-Cognitive and Hepatoprotective Effects in Vivo. Journal of Medicinal Chemistry, 2012, 55, 5231-5242.	6.4	72
82	Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 1222-1235.	3.0	52
83	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa. European Journal of Medicinal Chemistry, 2011, 46, 3118-3123.	5.5	43
84	Cardioprotective effect of NOâ€•metoprolol in murine coxsackievirus B3â€•induced myocarditis. Journal of Medical Virology, 2010, 82, 2043-2052.	5.0	6
85	Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: Novel heterocyclic templates for butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2946-2949.	2.2	8
86	Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. Arzneimittelforschung, 2010, 60, 229-237.	0.4	16
87	Investigation into the in vivo effects of five novel tacrine/ferulic acid and Î²-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm. Arzneimittelforschung, 2010, 60, 299-306.	0.4	9
88	Hybrid Molecules from Xanomeline and Tacrine: Enhanced Tacrine Actions on Cholinesterases and Muscarinic M₁ Receptors. Journal of Medicinal Chemistry, 2010, 53, 2094-2103.	6.4	45
89	Synthesis and Opioid Receptor Binding Affinities of 2-Substituted and 3-Aminomorphinans: Ligands for Î¼, Î´, and Î˙ Opioid Receptors. Journal of Medicinal Chemistry, 2010, 53, 402-418.	6.4	30
90	Univalent and Bivalent Ligands of Butorphan: Characteristics of the Linking Chain Determine the Affinity and Potency of Such Opioid Ligands. Journal of Medicinal Chemistry, 2009, 52, 7389-7396.	6.4	22

#	Article	IF	Citations
91	Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties. Bioorganic and Medicinal Chemistry, 2008, 16, 4252-4261.	3.0	91
92	Design and synthesis of tacrineâ€“ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2905-2909.	2.2	182
93	NO-Donating Tacrine Hybrid Compounds Improve Scopolamine-Induced Cognition Impairment and Show Less Hepatotoxicity. Journal of Medicinal Chemistry, 2008, 51, 7666-7669.	6.4	49
94	Synthesis and Biological Evaluation of NO-Donor-Tacrine Hybrids as Hepatoprotective Anti-Alzheimer Drug Candidates. Journal of Medicinal Chemistry, 2008, 51, 713-716.	6.4	118
95	A New Way of Data Interpretation for Cognition Tests in Rats Used to Characterise Six Choline Esterase Inhibitors with Heterocyclic Nitrogen Bridgehead Structure. Arzneimittelforschung, 2008, 58, 543-550.	0.4	0
96	Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters. Current Topics in Medicinal Chemistry, 2007, 7, 347-353.	2.1	23
97	Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties. Mini-Reviews in Medicinal Chemistry, 2007, 7, 221-229.	2.4	44
98	Acetylcholinesterase inhibitors based on carbamic acid quinolin-6-yl esters. Expert Opinion on Therapeutic Patents, 2007, 17, 733-736.	5.0	1
99	6-Aryl-4-Oxohexanoic Acids: Synthesis, Effects on Eicosanoid Biosynthesis,and Anti-Inflammatory In Vivo-Activities. Medicinal Chemistry, 2007, 3, 433-438.	1.5	11
100	Dopamine/Serotonin Receptor Ligands. 10:1SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D1, D2L, and D5Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D1/D5Selective Antagonist. Journal of Medicinal Chemistry, 2006, 49, 760-769.	6.4	78
101	Homobivalent Quinazolinimines as Novel Nanomolar Inhibitors of Cholinesterases with Dirigible Selectivity toward Butyrylcholinesterase. Journal of Medicinal Chemistry, 2006, 49, 5411-5413.	6.4	96
102	Dopamine/Serotonin Receptor Ligands. 12:â€‰ SAR Studies on Hexahydro-dibenz[d,g]azecines Lead to 4-Chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the First Picomolar D5-Selective Dopamine-Receptor Antagonist. Journal of Medicinal Chemistry, 2006, 49, 2110-2116.	6.4	37
103	Synthesis and Reactivity of Dibenz[d,g]azecin-14(5H)-ones. Heterocycles, 2006, 68, 879.	0.7	0
104	6-Hydroxy- and 6-methoxy-Î²-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5840-5843.	2.2	69
105	Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2006, 14, 1966-1977.	3.0	85
106	Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. European Journal of Medicinal Chemistry, 2005, 40, 305-313.	5.5	159
107	Synthesis and Vasorelaxant Properties of Hybrid Molecules Out of NO-Donors and the ?-Receptor Blocking Drug Propranolol.. ChemInform, 2005, 36, no.	0.0	1
108	Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the Î²-receptor blocking drug propranolol. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4995-4997.	2.2	15

#	Article	IF	Citations
109	Investigations into the mechanism of lactamization of lactones yielding in a novel route to biologically active tryptamine derivatives. Tetrahedron, 2004, 60, 4567-4578.	1.9	16
110	Dopamine/serotonin receptor ligands. Part VIII[1]:the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testings. European Journal of Medicinal Chemistry, 2004, 39, 481-489.	5.5	20
111	Dopamine/Serotonin Receptor Ligands. Part 3. Synthesis and Biological Activities of 7,7â€²-Alkylene-bis-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo [2,3-g]azecines â€" Application of the Bivalent Ligand Approach to a Novel Type of Dopamine Receptor Antagonist.. ChemInform, 2003, 34, no.	0.0	0
112	Dopamine/Serotonin Receptor Ligands. Part 4. Synthesis and Pharmacology of Novel 3-Benzazecines and 3-Benzazonines as Potential 5-HT2A and Dopamine Receptor Ligands.. ChemInform, 2003, 34, no.	0.0	0
113	Dopamine Receptor Ligands. Part VII [1]: Novel 3-Substituted 5-Phenyl-1, 2, 3, 4, 5, 6-hexahydro-azepino-[4, 5-b]indoles as Ligands for the Dopamine Receptors. Archiv Der Pharmazie, 2003, 336, 466-476.	4.1	19
114	Dopamine/Serotonin Receptor Ligands, Part III [1]: Synthesis and Biological Activities of 7, 7â€²â€"Alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines â€" Application of the Bivalent Ligand Approach to a Novel Type of Dopamine Receptor Antagonist. Archiv Der Pharmazie, 2002, 335, 367-373.	4.1	18
115	Dopamine/Serotonin Receptor Ligands. Part IV [1]: Synthesis and Pharmacology of Novel 3-Benzazecines and 3-Benzazonines as Potential 5-HT2A and Dopamine Receptor Ligands. Archiv Der Pharmazie, 2002, 335, 443-448.	4.1	25
116	Synthesis and Biological Evaluation of Flavonoidâ€Cinnamic Acid Amide Hybrids with Distinct Activity against Neurodegeneration in Vitro and in Vivo. Chemistry - A European Journal, 0, , .	3.3	4